推进基础和转化科学：GRAPPA 2023 年会基础科学研讨会亮点。
Advancing Basic and Translational Science: Highlights From the Basic Science Workshop at the GRAPPA 2023 Annual Meeting.
机构信息
M.E. Husni, MD, MPH, Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, Ohio;
C. Sun, Case Western Reserve University, Cleveland, Ohio.
出版信息
J Rheumatol. 2024 Oct 1;51(Suppl 2):84-88. doi: 10.3899/jrheum.2024-0459.
Contemporary translational and clinical research advances in psoriatic disease (PsD) were highlighted at the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2023 annual meeting basic science workshop. This year's workshop focused on key topics, including the significance of the annual GRAPPA meetings as a platform for collaboration and knowledge exchange. Discussions centered around expanding our understanding of tumor necrosis factor inhibitor (TNFi) treatment in PsD and enhancing early detection strategies for PsD comorbidities, specifically for the timely intervention and management of cardiovascular (CV) comorbidities. Insights on the role of the C-C chemokine receptor type 6 (CCR6) in PsD and psoriatic arthritis were provided, suggesting that blockade of CCR6 can reduce psoriasis-like dermatitis and joint inflammation in mouse models.
在 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis（GRAPPA）2023 年年会基础科学研讨会上，重点介绍了银屑病（PsD）的当代转化和临床研究进展。今年的研讨会重点关注了一些关键主题，包括作为合作和知识交流平台的 GRAPPA 年会的重要意义。讨论围绕着扩大我们对 TNF 抑制剂（TNFi）在 PsD 中的治疗作用的理解以及增强 PsD 合并症的早期检测策略展开，特别是为了及时干预和管理心血管（CV）合并症。会上还介绍了 C-C 趋化因子受体 6（CCR6）在 PsD 和银屑病关节炎中的作用，表明阻断 CCR6 可以减少小鼠模型中的银屑病样皮炎和关节炎症。
Zotero 插件